Secukinumab

Secukinumab, sold under the brand name Cosentyx, is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.[2][3] It inhibits a member of the cytokine family, interleukin 17A.[2] Contents 1 Medical uses 2 Adverse effects 3 Pharmacology 4 Chemistry 5 History 6 References 7 External links Medical uses S... [wikipedia]